Preliminary results of a phase I trial inspire the phase II KarMMa study of bb2121, an anti-B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T Cell therapy, for relapsed and refractory Multiple Myeloma (rrMM)

被引：0
|
作者：
Einsele, H. [1 ]
Goldschmidt, H. [2 ]
Weisel, K. [3 ]
Hege, K. [4 ]
Munshi, N. [5 ]
San Miguel, J. [6 ]
机构：
[1] Univ Clin Wuerzburg, Wurzburg, Germany
[2] Univ Clin Heidelberg, Heidelberg, Germany
[3] Univ Clin Tuebingen, Tubingen, Germany
[4] Celgene Corp, San Francisco, CA USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Clin Univ Navarra, Pamplona, Spain
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V409
引用
收藏
页码：134 / 134
页数：1
相关论文
共 50 条
  • [1] Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
    Raje, Noopur
    Berdeja, Jesus
    Lin, Yi
    Siegel, David
    Jagannath, Sundar
    Madduri, Deepu
    Liedtke, Michaela
    Rosenblatt, Jacalyn
    Maus, Marcela V.
    Turka, Ashley
    Lam, Lyh-Ping
    Morgan, Richard A.
    Friedman, Kevin
    Massaro, Monica
    Wang, Julie
    Russotti, Greg
    Yang, Zhihong
    Campbell, Timothy
    Hege, Kristen
    Petrocca, Fabio
    Quigley, M. Travis
    Munshi, Nikhil
    Kochenderfer, James N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (18): : 1726 - 1737
  • [2] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED KARMMA RESULTS
    Cavo, M.
    Oriol, A.
    San-Miguel, J.
    Kansagra, A.
    Madduri, D.
    Shah, N.
    Moreau, P.
    Yakoub-Agha, I.
    Delforge, M.
    Einsele, H.
    Goldschmidt, H.
    Weisel, K.
    Rambaldi, A.
    Reece, D.
    Rodriguez-Otero, P.
    Petrocca, F.
    Connarn, J.
    Patel, P.
    Huang, L.
    Campbell, T.
    Hege, K.
    Munshi, N.
    HAEMATOLOGICA, 2021, 106 (10) : 5 - 5
  • [3] Treatment of relapsed or refractory multiple myeloma with bb2121 chimeric antigen receptor T cells
    Stocker, Nicolas
    HEMATOLOGIE, 2021, 27 (02): : 46 - 47
  • [4] Idecabtagene Vicleucel (ide-cel, bb2121), A BCMA-Directed Car T cell therapy, in patients with Relapsed and Refractory Multiple Myeloma (RRMM): Initial KarMMa results
    Einsele, H.
    Weisel, K.
    Goldschmidt, H.
    Munshi, N. C.
    Anderson, L. D., Jr.
    Shah, N.
    Jagannath, S.
    Berdeja, J.
    Lonial, S.
    Raje, N.
    Siegel, D. S.
    Lin, Y.
    Oriol, A.
    Moreau, P.
    Yakoub-Agha, I
    Delforge, M.
    Petrocca, F.
    Connarn, J. N.
    Patel, P.
    Huang, L.
    Campbell, T. B.
    Hege, K.
    San Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 90 - 91
  • [5] The B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T Cell Therapy Idecabtagene Vicleucel (Ide-Cel; Bb2121) in Relapsed and Refractory Multiple Myeloma (Rrmm): Outcomes from a Phase 1 Study Support the Phase 3 Karmma-3 Study Design to Compare IDE-Cel Versus Standard Triplet Regimens
    Einsele, Hermann
    Raab, Marc
    Kroeger, Nicolaus
    Fenk, Roland
    Scheid, Christoph
    Munshi, Nikhil
    Petrocca, Fabio
    Hege, Kristen
    Novick, Steven
    Raje, Noopur
    Kochenderfer, James
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 213 - 213
  • [6] bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.
    Raje, Noopur S.
    Berdeja, Jesus G.
    Lin, Yi
    Munshi, Nikhil C.
    Samuel, David
    Siegel, DiCapua
    Liedtke, Michaela
    Jagannath, Sundar
    Madduri, Deepu
    Rosenblatt, Jacalyn
    Maus, Marcela Valderrama
    Turka, Ashley
    Lam, Lyh Ping
    Morgan, Richard A.
    Quigley, Travis
    Massaro, Monica
    Hege, Kristen
    Petrocca, Fabio
    Kochenderfer, James
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Monitoring anti-BCMA CAR T-Cell Therapy with bb2121 in relapsed multiple myeloma
    Seipel, K.
    Wiedemann, G.
    Jeker, B.
    Porret, N.
    Taleghani, B. Mansouri
    Bacher, U.
    Pabst, T.
    SWISS MEDICAL WEEKLY, 2021, 151 : 24 - 24
  • [8] Idecabtagene vicleucel (ide-cel; bb2121); a BCMA-directed CAR T cell therapy; for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
    Einsele, Hermann
    Anderson, Larry D., Jr.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus
    Lonial, Sagar
    Raje, Noopur
    Siegel, David S.
    Lin, Yi
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Goldschmidt, Hartmut
    Weisel, Katja
    Cavo, Michele
    Reece, Donna
    Rambaldi, Alessandro
    Truppel-Hartmann, Anna
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus
    Munshi, Nikhil C.
    Oriol, Albert
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 173 - 173
  • [9] FIRST-IN-HUMAN MULTICENTER STUDY OF BB2121 ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS
    Lin, Y.
    Berdeja, J.
    Raje, N.
    Munshi, N.
    Siegel, D.
    Liedtke, M.
    Jagannath, S.
    Maus, M.
    Turka, A.
    Lam, L. P.
    Hege, K.
    Morgan, R.
    Quigley, M. T.
    Kochenderfer, J.
    HAEMATOLOGICA, 2017, 102 : 21 - 21
  • [10] Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety
    Das, Saurav
    Ailawadhi, Sikander
    Sher, Taimur
    Roy, Vivek
    Fernandez, Andre
    Parrondo, Ricardo D.
    CURRENT ONCOLOGY, 2023, 30 (11) : 9627 - 9633
12345